Last $170.43 USD
Change Today -0.71 / -0.41%
Volume 3.1M
AGN On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Open
$172.94
Previous Close
$171.14
Day High
$174.32
Day Low
$170.15
52 Week High
06/30/14 - $174.49
52 Week Low
09/11/13 - $86.95
Market Cap
50.6B
Average Volume 10 Days
1.7M
EPS TTM
$5.14
Shares Outstanding
296.8M
EX-Date
08/13/14
P/E TM
33.2x
Dividend
$0.20
Dividend Yield
0.12%
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. It focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. The company has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,400 Employees
Last Reported Date: 02/25/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
President
Total Annual Compensation: $651.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $641.5K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Allergan to Cut 1,500 Jobs on Restructuring

Allergan announced that they will cut 1,500 jobs, or 13% of their workforce, and take a pretax charge of $375 million to $425 million for severance and other costs related to a restructuring.

Allergan Inc. Declares Dividend for Second Quarter of 2014, Payable on September 5, 2014

Allergan Inc. announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 5, 2014 to stockholders of record on August 15, 2014.

Allergan Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for Third Quarter of 2014, Full Year 2014, 2015 and 2016

Allergan Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net earnings attributable to the company of $417.2 million or $1.37 per diluted share on revenues of $1,864.2 million compared to net earnings attributable to the company of $359.9 million or $1.19 per diluted share on revenues of $1,597.7 million a year ago. Operating income was $607.9 million compared to $493.2 million a year ago. Earnings from continuing operations before income taxes was $574.4 million compared to $486.4 million a year ago. Earnings from continuing operations was $418.4 million or $1.37 per diluted share compared to $354.0 million or $1.17 per diluted share a year ago. Non-GAAP net earnings attributable to the company of $368.6 million or $1.51 per diluted share on revenues of $1,854.5 million compared to net earnings attributable to the company of $359.9 million or $1.22 per diluted share on revenues of $1,597.7 million a year ago. Non-GAAP operating income was $659.7 million compared to $525.8 million a year ago. Non-GAAP earnings from continuing operations before income taxes was $637.5 million compared to $507.8 million a year ago. Non-GAAP earnings from continuing operations was $460.3 million or $1.51 per diluted share compared to $369.9 million or $1.22 per diluted share a year ago. For the six months period, the company reported net earnings attributable to the company of $674.5 million or $2.22 per diluted share on revenues of $3,510.3 million compared to net earnings attributable to the company of $664.8 million or $1.23 per diluted share on revenues of $3,057.3 million a year ago. Operating income was $989.8 million compared to $864.3 million a year ago. Earnings from continuing operations before income taxes was $936.0 million compared to $833.0 million a year ago. Earnings from continuing operations was $676.9 million or $2.22 per diluted share compared to $627.0 million or $2.06 per diluted share a year ago. Non-GAAP net earnings attributable to the company of $817.4 million or $2.69 per diluted share on revenues of $3,500.6 million compared to net earnings attributable to the company of $359.9 million or $2.20 per diluted share on revenues of $3,057.3 million a year ago. Non-GAAP operating income was $1,175.3 million compared to $913.1 million a year ago. Non-GAAP earnings from continuing operations before income taxes was $1,134.8 million compared to $507.8 million a year ago. Non-GAAP earnings from continuing operations was $819.2 million or $2.69 per diluted share compared to $668.0 million or $2.20 per diluted share a year ago. For the full year of 2014, the company expects total product net sales between $6,900 million and $7,050 million, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business. The company expects non-GAAP cost of sales to product net sales ratio at approximately 12.5%; non-GAAP selling, general and administrative expenses to product net sales ratio between 37% and 38%; non-GAAP research and development expenses to product net sales ratio at approximately 16.5%; non-GAAP diluted earnings per share attributable to stockholders between $5.74 and $5.80; and effective tax rate on non-GAAP earnings between 26% and 27%. GAAP diluted earnings per share attributable to the company stockholders from continuing operations in the range of $5.16 to $5.22. For the third quarter of 2014, the company expects total product net sales between $1,675 million and $1,750 million, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business; and non-GAAP diluted earnings per share attributable to stockholders between $1.44 and $1.47. The company expects GAAP diluted earnings per share attributable to the company stockholders from continuing operations in the range of $1.38 to $1.41. For 2014, EPS is estimated between $5.74 and $5.80. For 2015, the company expects EPS between $8.20 and $8.40. For 2016, the company expects EPS at approximately $10.00.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $170.43 USD -0.71

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $216.37 USD +0.24
Astellas Pharma Inc ¥1,415 JPY +10.50
Mylan Inc/PA $52.06 USD +0.67
Regeneron Pharmaceuticals Inc $306.02 USD +2.29
Shire PLC 4,955 GBp -16.00
View Industry Companies
 

Industry Analysis

AGN

Industry Average

Valuation AGN Industry Range
Price/Earnings 39.2x
Price/Sales 7.6x
Price/Book 7.5x
Price/Cash Flow 36.3x
TEV/Sales 6.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.